Evidence map›Paper›PMID 38052529›Full record

ArticleMathematical biosciences and engineering : MBE2023

Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer.

Ernesto A B F Lima, Patrick N Song, Kirsten Reeves, Benjamin Larimer, Anna G Sorace, Thomas E Yankeelov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mathematical biosciences and engineering : MBE, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. [Nuclear medicine and biology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ernesto A B F LimaOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, 201 East 24th St, Austin, TX 78712, USA.
Patrick N SongDepartment of Radiology, The University of Alabama at Birmingham, 619 19th St S, Birmingham, AL 35294, USA.
Kirsten ReevesDepartment of Radiology, The University of Alabama at Birmingham, 619 19th St S, Birmingham, AL 35294, USA.
Benjamin LarimerDepartment of Radiology, The University of Alabama at Birmingham, 619 19th St S, Birmingham, AL 35294, USA.
Anna G SoraceDepartment of Radiology, The University of Alabama at Birmingham, 619 19th St S, Birmingham, AL 35294, USA.
Thomas E YankeelovOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, 201 East 24th St, Austin, TX 78712, USA.
University of Alabama at Birmingham · USLivestrong Foundation · USThe University of Texas at Austin · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCERU24CA226110 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LEWIS, MICHAEL T., RUBIN, DANIEL L · 2019 to 2023
$3.2M
UAB Predoctoral Training Grant in Translational and Molecular SciencesT32GM135028 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Mythreye Karthikeyan, RAKESH P. PATEL · 2021 to 2026
$1.6M
Personalizing immunotherapy in HER2+ breast cancer through quantitative imagingR01CA240589 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C · 2020 to 2023
$1.6M
Mathematical modeling and molecular imaging to maximize response while minimizing toxicities from systemic therapies in preclinical models of breast cancerR01CA276540 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C, YANKEELOV, THOMAS E · 2023 to 2025
$1.4M
NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA240589NCI NIH HHS R01 CA276540NCI NIH HHS U24 CA226110NIGMS NIH HHS T32 GM135028
6 · The paper itself

Abstract

The goal of this study is to develop a mathematical model that captures the interaction between evofosfamide, immunotherapy, and the hypoxic landscape of the tumor in the treatment of tumors. Recently, we showed that evofosfamide, a hypoxia-activated prodrug, can synergistically improve treatment outcomes when combined with immunotherapy, while evofosfamide alone showed no effects in an

Indexed as

AdenocarcinomaColonic NeoplasmsAnimalsCell HypoxiaCell Line, TumorDisease Models, AnimalHypoxiaImmunotherapyMiceMisonidazoleNitroimidazolesPhosphoramide MustardsTumor MicroenvironmentfluoromisonidazoleMisonidazoleNitroimidazolesPhosphoramide MustardsTH 302[hypoxiaimmunotherapy modelmodel calibrationmousetumor growth modeluncertainty quantification

Identifiers

PMID38052529
PMCPMC10703000
OpenAlexW4389397498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.